A Pan-Cancer Analysis Reveals CLEC5A as a Biomarker for Cancer Immunity and Prognosis

A Pan-Cancer Analysis Reveals CLEC5A as a Biomarker for Cancer Immunity and Prognosis

BackgroundCLEC5A is a member of the C-type lectin superfamily. It can activate macrophages and lead to a series of immune-inflammation reactions. Previous studies reveal the role of CLEC5A in infection and inflammation diseases.MethodWe acquire and analyze data from The Cancer Genome Atlas (TCGA) da...

Full description

Bibliographic Details
Main Authors: Rui Chen, Wantao Wu, Si-Yu Chen, Zheng-Zheng Liu, Zhi-Peng Wen, Jing Yu, Long-Bo Zhang, Zaoqu Liu, Jian Zhang, Peng Luo, Wen-Jing Zeng, Quan Cheng
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-08-01
Series:Frontiers in Immunology
Subjects:
pan-cancer
CLEC5A
prognostic biomarkers
cancer immune
immunotherapy
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.831542/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2022.831542/full

Similar Items